弥漫大B细胞淋巴瘤患者蛋白质谱与淋巴瘤标志物表达的相关性研究

Correlated research between protein spectrometry and lymphoma markers for DLBCL patients

目的 研究弥漫大B细胞淋巴瘤(DLBCL)患者血清蛋白质谱表达与淋巴瘤标志物的相关性,进一步研究该蛋白与DLBCL预后的关系.方法 SELDI技术WCX2芯片检测62例DLBCL患者蛋白质谱,生物化学方法测定乳酸脱氢酶(LDH),酶联免疫吸附法(ELISA)测定β2-微球蛋白(β2-MG)和癌抗原125(CA125).分析DLBCL患者11×103～12×103蛋白阳性组与阴性组间LDH、β2-MG、CA125的水平,同时作相关性分析及生存期分析.结果 11×103～12×103蛋白阳性组LDH、β2-MG、CA125水平分别为(523.30±435.96)U/L、(3.23±1.24)mg/L、(81.07±61.39)U/L,明显比阴性组高(P＜0.05).该蛋白峰值与LDH、β2-MG、CA125呈正相关(P＜0.01).该蛋白阳性组中位生存期11个月,生存期明显短于阴性组(P＜0.01).LDH正常组生存期明显长于增高组(P＜0.01),而β2-MG、CA125生存期差异无统计学意义.结论 11×103～12×103蛋白有望与LDH联合作为DLBCL患者的预后指标.

Objective To research correlation of serum protein spectrometry and lymphoma markers for diffuse large B cell lymphoma (DLBCL) patients. Whether there is relative between the protein and prognosis will be further researched. Methods Serum protein spectrometry of 62 DLBCL patients was detected by the SELDI-TOF-MS technique and Weak cation exchange 2 (WCX2) chip. Lactate dehydrogenase (LDH) was detected by biochemistry method. Beta-2-microglobulin (β2-MG) and cancer antigen125(CA125)were detected by enzyme-linked immunosorbent assay (ELISA). The level of LDH, β2-MG and CA125 for DLBCL patients between 11×103～12×103 protein expressed positively and negatively was analyzed. Meanwhile,correlation analysis and survival analysis were done. Results LDH, β2-MG and CA125 in 11×103～12×103protein expressed positive group were (523.30±435.96)U/L, (3.23±1.24)mg/L, (81.07±61.39)U/L respectively,and they were higher than that in negative group (P＜0.05). 11×103～12×103 protein was positive correlated to LDH, β2-MG and CA125 (P＜0.01). The survival time in 11×103～12×103 protein expressed in positive group,in which median survival time was 11 months, was shorter than that in negative group(P ＜0.01). The survival time in LDH normal group was longer than that in increased group(P ＜0.01). The survival time of β2-MG and CA125 had no significant difference between increased group and normal group. Conclusion LDH and 11×103～12×103 protein are expected to be prognosis indicators for DLBCL patients.